Eyeworld

88 | EYEWORLD | SPRING 2024 C ORNEA "After we've done all [this] testing, then we determine the stage of LSCD," she said. "Based on the severity of the LSCD, we treat the pa- tients accordingly." Often, Dr. Deng said these patients have other comorbidities, such as ocular surface inflammation, dry eye disease, or eyelid abnor- malities. In many of these eyes, their stem cell function improves as a result of removing the insulting agents, she said. As a majority of eyes with LSCD still have residual LSCs, once the health of the ocular surface improves, many of these eyes can recover quite well and subse- quently, their vision improves. The choice of treatment, Dr. Deng said, will depend on the stage of LSCD. If the patient does not recover by the optimization of the ocular surface—for example taking a holiday from contact lens use in LSCD induced by soft contact lens wear—Dr. Deng said she might proceed with a scleral lens, which can protect the cornea and can improve the vision. "This is a really good device for eyes with severe dry eyes in addition to LSCD," she said. Dr. Deng said she has had success treating LSCD resulting from prior glaucoma surgeries with scleral lenses. For more severe cases of LSCD, Dr. Deng will move to surgery. She has performed the SLET procedure as the preferred option if the disease affects only one eye. Another option, she said, if the patient has bilateral severe disease, is to use the Boston KPro. "If they have contact lens intolerance or have a severe cornea scar that a contact lens wouldn't improve the vision, then KPro would be a good option," she said. Dr. Deng is also currently recruiting for a Phase 1 clinical trial investigating cultivated autologous limbal stem cells. If patients meet inclusion criteria, a tiny limbal tissue is removed from one eye, and the limbal stem cells are grown on a dish. Once there are enough stem cells, they are transplanted back to the diseased eye, she said. Dr. Deng also has experience and success with using allogeneic stem cell transplantation with systemic immunosuppression for these patients with severe bilateral disease. However, she noted that she doesn't employ this option as often because of a lack of interest in her patient population. "Our patients mostly are elderly patients, and they are not very keen on immunosuppression," she said. She noted that stem cell transplantation with immunosuppression is an option, adding that it has been shown to be safe by Dr. Holland and others. "I think it's patient's selection and whether the center has the expertise to do that," she said. "I did collaborate with a team of renal transplant surgeons and internists to man- age those patients. I have to congratulate Dr. Holland on their success because it's very labor intensive, and it takes commitment on him, the renal transplant team, and the patient to man- age the postoperative care and immunosuppres- sion properly. It is a matter of disseminating the knowledge and protocol to other ophthalmolo- gists so that they can adapt the protocol." Dr. Deng said that we want our trainees to be exposed to various procedures and therapies. "The fellows and residents are here to get ex- posed to how we make the diagnosis, stage the disease, using multimodal in vivo imaging. First, the fluorescein straining pattern is carefully ex- amined to detect stippling staining in a whorl- like pattern, Next, an anterior segment optical coherence tomography is performed to detect whether a hyporeflective epithelial layer is present on the cornea and limbus. Lastly, in vivo confocal microscopy is performed to evaluate whether corneal and limbal epithelial cells are present in high density." These in vivo imaging tests are a fast way to make the correct diagno- sis of LSCD, she said. "We also perform impres- sion cytology to confirm presence of conjuncti- val cells on the cornea, which is the hallmark of limbal stem cell deficiency," Dr. Deng said. "The trainees are exposed to the surgical techniques of limbal stem cell transplantation and amni- otic membrane graft for partial deficiency. Our trainees here have well rounded exposure to the diagnosis and management of limbal stem cell deficiency." Dr. Deng stressed the importance of not jumping into limbal stem cell transplant for these patients before ensuring that you've made the correct diagnosis and staged the disease. "Without knowing whether the eye has lim- bal stem cell deficiency or at what degree of severity, the treatment selection might not be appropriate," she said. "It's very important that the disease is correctly diagnosed and staged so the appropriate treatment can be given to the patient with the least invasive way to treat this disease." continued from page 87 continued on page 90

• Blank Page
• Blank Page (1)